# Phase II Study With Ga101-DHAP as Induction Therapy in Relapsed/Refractory DLBCL Patients

> **NCT02374424** · PHASE2 · TERMINATED · sponsor: **Fondazione Italiana Linfomi - ETS** · enrollment: 29 (actual)

## Conditions studied

- Diffuse, Large B-Cell, Lymphoma

## Interventions

- **DRUG:** GA101_DHAP

## Key facts

- **NCT ID:** NCT02374424
- **Lead sponsor:** Fondazione Italiana Linfomi - ETS
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-11-05
- **Primary completion:** 2018-02
- **Final completion:** 2020-06-23
- **Target enrollment:** 29 (ACTUAL)
- **Why stopped:** Interim analysis planned as per protocol didn't provide positive outcome therefore enrollment was not reopened. However, the enrolled patients concluded therapy and continued into the follow-up phase. The study was closed only after LVLP.
- **Last updated:** 2022-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02374424

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02374424, "Phase II Study With Ga101-DHAP as Induction Therapy in Relapsed/Refractory DLBCL Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02374424. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*